You are here
Who are we:
Novosanis is a Belgian-based medical device company, founded on March 12, 2013 as a spin-off company from the University of Antwerp, Belgium. Since 2019, it is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR).
Our medical devices aim to meet all regulatory and quality requirements. Novosanis is an ISO13485 certified company endorsed on multiple occasions nationally and internationally for its solutions.
Novosanis has a core team of 20+ members situated at the headquarters in Wijnegem, Belgium. However, our team members are spread across the globe, with presence in the EU (Belgium, the Netherlands, Spain, UK), Asia (Japan), and North America (US and Canada). The group consists of range of experts in (bio) medical sciences, product design & development, (biomedical) engineering, sales, business development, marketing, communication, quality & regulatory affairs as well as (clean area) production.
Colli-Pee®, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes (4 mL to 45 mL*) for different application purposes.
Urine collection through Colli-Pee® is easy, comfortable and more accurate than a regular urine cup. Additionally, first-void urine collection has shown to improve detection of infectious diseases, including sexually transmitted infections as well as some cancers. Colli-Pee® enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen.
*Some Novosanis products are in development or not available in all geographic regions. Contact us to know the registration status in your region.
Interested to learn more about our journey, our Colli-Pee product, as well as our team?
Watch our corporate video below.
Awards, achievements and certifications:
Novosanis has been co-awarded a CASUS grant by Eurostars, a European Union (EU) program dedicated to support R&D-performing Small and Medium Sized Enterprises (SMEs).
Novosanis was audited by SGS Belgium. During the assessment, Novosanis, the Belgium based medical device company demonstrated to meet all the requirements of the ISO13458:2016 quality standards.
The European Commission granted a “Seal of Excellence” to Novosanis’ project proposal UROSCREEN on the use of Colli-Pee® in cervical cancer screening programs.
Novosanis awarded the best MedTech master project during the Best of PO Awards from the Faculty Design Sciences and Product Development at the University of Antwerp.
Colli-Pee®, a first void urine collection device, developed by Novosanis has received the IWT Innovation Award in the category “major social relevance”. Novosanis is very honored with this prize which was granted by The Agency for Innovation by Science and Technology.
Novosanis has been awarded the prestigious Henry Van de Velde Award in Design for Healthcare for their innovative urine sampling device Colli-Pee®.